Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A GLP-1/glucagon dual receptor agonist co-developed by Innovent Biologics and Eli Lilly. Mazdutide has shown strong weight loss results in Chinese clinical populations, with Phase 3 data showing up to 17.4% weight loss at 48 weeks. It received approval in China in late 2025 for obesity treatment, making it one of the first dual agonists to reach market anywhere in the world.
A GLP-1/glucagon dual receptor agonist developed by Altimmune, similar in mechanism to survodutide. In Phase 2 trials (MOMENTUM), pemvidutide demonstrated up to 15.6% weight loss at 48 weeks with notable preservation of lean body mass — a differentiating feature compared to other weight loss drugs where significant muscle loss is a concern.
Dual agonism of GLP-1 and glucagon receptors, similar to survodutide and pemvidutide. GLP-1 activation suppresses appetite and slows gastric emptying. Glucagon activation increases energy expenditure and hepatic fat oxidation. The dual mechanism targets both sides of the energy balance equation.
Activates both GLP-1 and glucagon receptors. GLP-1 reduces appetite and food intake. Glucagon activation increases energy expenditure, promotes fat oxidation, and may help preserve lean mass during weight loss by shifting energy substrate utilization toward fat rather than protein catabolism.
- Weight management (approved in China)
- Type 2 diabetes (investigational)
- Metabolic syndrome
- Weight management (investigational)
- MASH/NASH treatment (investigational)
- Lean mass preservation during weight loss
- GI side effects (nausea, vomiting, diarrhea)
- Not yet approved outside China
- Potential blood sugar effects from glucagon component
- Long-term safety data still accumulating
- GI side effects (nausea, diarrhea)
- Still in clinical trials — full safety profile not established
- Potential blood sugar effects
- Injection site reactions
Approved in China (late 2025) for obesity. Not yet submitted to FDA. Global Phase 3 trials ongoing. Represents the first approved GLP-1/glucagon dual agonist globally. US regulatory pathway unclear — may require separate US clinical program.
Phase 2 completed (MOMENTUM trial). Phase 2b for MASH (IMPACT trial) ongoing. Altimmune reported 15.6% weight loss at 48 weeks with lean mass preservation. Phase 3 planning underway. The lean mass preservation claim is a key differentiator if confirmed in larger trials.
- Pemvidutide Phase 2 MOMENTUM trial results
2024 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.